KemPharm Financial Statements From 2010 to 2024
| KMPHDelisted Stock | USD 5.81 0.02 0.34% |
Check KemPharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among KemPharm main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . KemPharm financial statements analysis is a perfect complement when working with KemPharm Valuation or Volatility modules.
KemPharm |
KemPharm Company Return On Asset Analysis
KemPharm's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current KemPharm Return On Asset | -0.0897 |
Most of KemPharm's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, KemPharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, KemPharm has a Return On Asset of -0.0897. This is 98.97% lower than that of the Pharmaceuticals sector and 99.62% lower than that of the Health Care industry. The return on asset for all United States stocks is 35.93% lower than that of the firm.
KemPharm Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining KemPharm's current stock value. Our valuation model uses many indicators to compare KemPharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across KemPharm competition to find correlations between indicators driving KemPharm's intrinsic value. More Info.KemPharm is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value KemPharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for KemPharm's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the KemPharm's earnings, one of the primary drivers of an investment's value.About KemPharm Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include KemPharm income statement, its balance sheet, and the statement of cash flows. KemPharm investors use historical funamental indicators, such as KemPharm's revenue or net income, to determine how well the company is positioned to perform in the future. Although KemPharm investors may use each financial statement separately, they are all related. The changes in KemPharm's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on KemPharm's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on KemPharm Financial Statements. Understanding these patterns can help to make the right decision on long term investment in KemPharm. Please read more on our technical analysis and fundamental analysis pages.
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in KemPharm Stock
If you are still planning to invest in KemPharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the KemPharm's history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |